Quell Therapeutics Appoints Experienced Biopharma Leader Luke Beshar as Independent Chair of its Board of Directors London, UK – July 10, 2024 – Quell Therapeutics Ltd (“Quell”), a world leader in...
Progress in the LIBERATE trial was presented at the American Transplant Congress today London, UK– June 4, 2024 – Quell Therapeutics Ltd (“Quell”), a leader in developing engineered...
Data demonstrating Quell's ability to engineer Tregs to enhance their specific targeting and durability while maintaining their suppressive function and phenotypic stability to be presented in Oral...
AstraZeneca signs $2 billion agreement with Quell to develop cell therapies
Collaboration brings together Quell™s proprietary multi-modular T-regulatory (Treg) cell engineering and manufacturing expertise with AstraZeneca™s proven development and commercial capabilities as...
Under the terms of the agreement, Quell and Cellistic will collaborate in joint research to develop a process for differentiating iPSCs into highly functional Treg cell therapy products. Quell will contribute its Treg expertise and engineering technologies, as well as characterising resulting Treg cells, while Cellistic will be responsible for the iPSC process science and development activities.
Fierce 15 winner Quell Therapeutics has nabbed a huge $156 million series B round for its new-look cell therapy work.